Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3610]

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric...

ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free

ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free

ASCO 2025: Sacituzumab govitecan helps some patients with PD-L1-positive triple-negative breast cancer live longer without cancer progression

ASCO 2025: Sacituzumab govitecan helps some patients with PD-L1-positive triple-negative breast cancer live longer...

ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer

ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer

New biomarker may guide best use of KRAS inhibitors in lung cancer

New biomarker may guide best use of KRAS inhibitors in lung cancer

New understanding of a decades-old bladder cancer treatment could help improve immunotherapies more broadly

New understanding of a decades-old bladder cancer treatment could help improve immunotherapies more broadly

ASCO 2025: Immune checkpoint inhibitors ‘high-risk yet promising’ for cancer patients who undergo organ transplant

ASCO 2025: Immune checkpoint inhibitors ‘high-risk yet promising’ for cancer patients who undergo organ transplant

Dual action immunotherapy in CAR-T cells improves control of B-ALL progression

Dual action immunotherapy in CAR-T cells improves control of B-ALL progression

Stratifying the immune landscape of tongue cancer

Stratifying the immune landscape of tongue cancer

ASCO 2025: Study demonstrates improved survival with combination of lurbinectedin and atezolizumab for extensive-stage small cell lung cancer

ASCO 2025: Study demonstrates improved survival with combination of lurbinectedin and atezolizumab for extensive...

More from ecancer